Fierce Pharma
OCTOBER 1, 2024
Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state, according to separate Worker Adjustment and Retraining Notification (WARN)
MedCity News
OCTOBER 3, 2024
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 3, 2024
Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.
PharmaVoice
OCTOBER 8, 2024
This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions and leaders who are not only navigating these changes, but at times, forging new paths for others to follow.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
OCTOBER 7, 2024
The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.
European Pharmaceutical Review
OCTOBER 7, 2024
New results from a first-of-its-kind study reports that a CAR-T cell therapy provided similar efficacy and safety to relapsed or refractory multiple myeloma patients administered with the treatment in clinical trials. For example, of the 236 patients who received infusions of ciltacabtagene autoleucel (cilta-cel), data shows that 89 percent responded to the treatment.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 3, 2024
More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.
pharmaphorum
OCTOBER 4, 2024
Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).
PharmaTech
OCTOBER 3, 2024
Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.
PharmaVoice
OCTOBER 7, 2024
Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.
European Pharmaceutical Review
OCTOBER 4, 2024
A study has reported an approach for optimising metronidazole colonic delivery systems, to increase their potential efficacy when treating diverticulitis. Researchers developed intestinal colon-coated sustained-release matrix metronidazole tablets, using a Quality by Design (QbD) approach. Arévalo-Pérez et al. noted that metronidazole is a synthetic nitroimidazole and has activity against anaerobic bacteria.
Fierce Pharma
OCTOBER 4, 2024
After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.
MedCity News
OCTOBER 2, 2024
SCAN Health Plan and Astrana Health recently launched SCAN Allied, a Medicare Advantage plan designed for the Asian older adult population. It includes access to a network of culturally competent providers, specialists and pharmacies from Astrana Health. The post SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults appeared first on MedCity News.
pharmaphorum
OCTOBER 2, 2024
A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
OCTOBER 3, 2024
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.
PharmaTimes
OCTOBER 2, 2024
ISM001-055 shows promise in improving lung function among patients
Clarivate
OCTOBER 2, 2024
Funders, governments and institutions across the globe are increasingly expected to demonstrate the societal impact of research. They need to answer questions such as: has investment in research and experimental development (R&D) yielded tangible benefits to individuals, communities, organizations and economies across diverse areas such as health, climate change and technological advancement?
Fierce Pharma
OCTOBER 2, 2024
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s riva | A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
MedCity News
OCTOBER 2, 2024
Alpine Physician Partners — which operates primary care organizations in several states — is implementing Ambience Healthcare’s documentation and coding tool after a successful pilot. Before adopting Ambience’s tool, Alpine clinicians spent 4.7 hours on charting per day, but now that time has dropped down to 1.2 hours per day. The post How A Physician Group Is Using AI to Save Clinicians 3+ Hours Per Day on Documentation appeared first on MedCity News.
pharmaphorum
OCTOBER 2, 2024
In a bold move to tackle soaring drug costs, Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the cost of Humira by 90%
Pharmaceutical Technology
OCTOBER 2, 2024
The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.
Pharmaceutical Commerce
OCTOBER 7, 2024
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, explains how pending legislation can improve patient access, and how these are helping with recognizing pharmacists as HCPs.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmaTimes
OCTOBER 3, 2024
Phase 1 trial of IRL757 demonstrates good absorption and safety profile
Fierce Pharma
OCTOBER 2, 2024
Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31
MedCity News
OCTOBER 6, 2024
Hospitals are facing increasingly burdensome policies from commercial insurers, leading to problems with cash flow and patient safety. Hospital executives think federal regulators need to enact stricter policies that require payers to operate on faster timelines, as well as provide more transparency into their reasons for denying claims. The post Payers Are Putting Profit Over Patients with Denials and Prior Auth Policies, Hospitals Say appeared first on MedCity News.
pharmaphorum
OCTOBER 7, 2024
UK Health Secretary Wes Streeting has announced plans to allow NHS England to share primary care data with scientific researchers, taking on some of the responsibility held by GPs. The minister told the Royal College of General Practitioners (RCGP) annual conference that, while many UK patients have given their consent for their data to be shared with studies run by the likes of the UK Biobank, Genomics England, and Our Future Health, they "still see, far too often, that this data is not shared
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Pharmaceutical Technology
OCTOBER 3, 2024
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.
European Pharmaceutical Review
OCTOBER 1, 2024
A paper has demonstrated a novel application of optimising processes to implement inverse design in pharmaceutical manufacturing. Machine learning techniques were assessed for use as a surrogate model to optimise a three-unit wet-granulation based flowsheet model for the manufacture of solid dosage forms. Dan et al. highlighted that recent research has begun to investigate the potential applications of deep learning in process development, however currently, use of this technique in this area
PharmaVoice
OCTOBER 1, 2024
Mark your calendars for the most important industry conferences in 2025.
Fierce Pharma
OCTOBER 7, 2024
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said.
Expert insights. Personalized for you.
340 
Let's personalize your content